The House of Lords Environment and Climate Change Committee continues its inquiry into Pet Parasite Medications (PPMs), with recent testimony from industry representatives on June 17. Dr. Donal Murphy, deputy CEO of the National Office of Animal Health (NOAH), alongside Dr. Ian Wright from the parasite control advisory body ESCCAP, and Dr. Jacqui Skelly of health products supplier Elanco, provided insights during the session.
Read More
This inquiry was prompted by concerns from the Veterinary Medicines Directorate (VMD) and the Environment Agency regarding the chemicals fipronil and imidacloprid found in British watercourses, which could harm local ecosystems. The VMD is considering changing the sale status of certain pet parasite treatments, potentially limiting their distribution to veterinarians, pharmacists, or qualified personnel in stores.
NOAH emphasized the critical role of risk-based parasite prevention in maintaining animal health and welfare. During the testimony, Dr. Murphy argued that any regulatory changes should take into account the comprehensive impact on parasite management, including animal welfare, environmental safety, responsible usage, access to treatments, and the potential risks that may arise from increased parasite infestations.
Dr. Murphy stated, "Our pets rely on us to keep them safe, healthy, and free from avoidable distress. Effective parasite control is a key part of that responsibility, helping to protect pets from parasites that can cause discomfort, pain, and, in some cases, serious health problems." He affirmed that the animal health industry is collaborating with professionals to promote evidence-based and risk-oriented parasite control methods, ensuring pet owners receive adequate information to make informed decisions.